RxSight Reports Q1 2026 Sales of $30.9M, Net Loss Widens, Reiterates Full-Year Guidance

RxSight, Inc.

2026-Q1 EPS reported -$0.38 revenue$30,893,000

Q1 2026 sales of $30.9M, down 18.5% YoY, driven by 27,472 Light Adjustable Lens units sold.
20 Light Delivery Devices sold in Q1, expanding installed base to 1,154 units.
Net loss of $(15.9)M ($(0.38)/share) vs $(8.2)M ($(0.20)/share) in Q1 2025.
Cash, equivalents and short-term investments totaled $217.9M as of March 31, 2026.
2026 revenue guidance reiterated at $120M-$135M; gross margin 70%-72%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

RxSight, Inc. reported the quarter ended March 31, 2026 results: revenue sales of $30.9 million, net income net loss of $(15.9) million, EPS $(0.38) per basic and diluted share. Guidance reaffirmed.

Period: the quarter ended March 31, 2026
Revenue: sales of $30.9 million
Net income: net loss of $(15.9) million
EPS: $(0.38) per basic and diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

– May 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026. Strategic Highlights and Recent Developments • Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units • 20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units • Robust clinical data presented at

View on SEC.gov

Browse all earnings releases →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-208912

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.